Mendez v. Global Institute Of Stem Cell Therapy And Research, USA

CourtDistrict Court, S.D. California
DecidedJuly 29, 2022
Docket3:20-cv-00915
StatusUnknown

This text of Mendez v. Global Institute Of Stem Cell Therapy And Research, USA (Mendez v. Global Institute Of Stem Cell Therapy And Research, USA) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mendez v. Global Institute Of Stem Cell Therapy And Research, USA, (S.D. Cal. 2022).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 CHRISTINA MENDEZ, individually and Case No.: 20cv915-LL-BLM on behalf of all others similarly situated, 12 ORDER DISMISSING COMPLAINT Plaintiff, 13 WITH LEAVE TO AMEND AND v. DENYING MOTION TO DISMISS 14 AS MOOT GLOBAL INSTITUTE OF STEM CELL 15 THERAPY AND RESEARCH, USA, et [ECF Nos. 15, 16] 16 al.,

17 Defendants. 18 19 20 In this putative consumer class action, Plaintiff Christina Mendez alleges federal 21 jurisdiction on the basis of the Class Action Fairness Act of 2005, 28 U.S.C. § 1332(d) 22 (“CAFA”). ECF No. 15. Pending before the Court is Plaintiff’s operative First Amended 23 Complaint (“FAC”), id., and a Motion to Dismiss the FAC filed by Global Institute of Stem 24 Cell Therapy and Research, USA (“Giostar”), Giostar Labs, Inc. (“Giostar Labs”), Anand 25 Srivastava, Deven Patel, Siddharth Bhavsar, and Scott Kirkpatrick (together, 26 “Defendants”), ECF No. 16. For the reasons discussed below, this action is DISMISSED 27 WITHOUT PREJUDICE for failure to sufficiently allege federal subject matter 28 jurisdiction. Defendants’ motion to dismiss is therefore DENIED WITHOUT 1 PREJUDICE as moot. Plaintiff is granted leave to amend her complaint pursuant to 2 28 U.S.C. § 1653. 3 I. BACKGROUND 4 Plaintiff filed this putative consumer class action complaint on May 15, 2020. ECF 5 No. 1. The operative FAC was filed on July 27, 2020. ECF No. 15. The FAC asserts the 6 following claims: (1) violation of California’s Unfair Competition Law (“UCL”), Cal. Bus. 7 & Prof. Code §§ 17200 et seq.; (2) violation of California’s False Advertising Law 8 (“FAL”), Cal. Bus. & Prof. Code §§ 17500 et seq.; (3) violation of California’s Consumers 9 Legal Remedies Act (“CLRA”), Cal. Civ. Code. §§ 1750 et seq.; (4) breach of express 10 warranty; (5) quasi contract; (6) breach of fiduciary duty; (7) fraudulent concealment; (8) 11 intentional misrepresentation; and (9) negligent misrepresentation. Id. Defendants’ motion 12 to dismiss was filed on August 31, 2020. ECF No. 16. 13 II. LEGAL STANDARD 14 “It is to be presumed that a cause lies outside [of federal courts’] limited jurisdiction, 15 and the burden of establishing the contrary rests upon the party asserting jurisdiction.” 16 Kokkonen v. Guardian Life Ins. Co. of Am., 511 U.S. 375, 377 (1994) (citations omitted). 17 Federal courts are constitutionally required to raise issues related to federal subject matter 18 jurisdiction and may do so sua sponte. Arbaugh v. Y&H Corp., 546 U.S. 500, 514 (2006). 19 A federal court must satisfy itself of its jurisdiction over the subject matter before 20 proceeding to the merits of the case. Ruhrgas AG v. Marathon Oil Co., 526 U.S. 574, 577, 21 583 (1999); Snell v. Cleveland, 316 F.3d 822, 826 (9th Cir. 2002) (“Federal Rule of Civil 22 Procedure 12(h)(3)[] provides that a court may raise the question of subject matter 23 jurisdiction, sua sponte, at any time during the pendency of the action . . . .”) (footnote 24 omitted). “A plaintiff suing in a federal court must show in his pleading, affirmatively and 25 distinctly, the existence of whatever is essential to federal jurisdiction, and, if he does not 26 do so, the court, on having the defect called to its attention or on discovering the same, 27 must dismiss the case, unless the defect be corrected by amendment.” Tosco Corp. v. 28 1 Cmtys. for a Better Env’t, 236 F.3d 495, 499 (9th Cir. 2001) (citation omitted), abrogated 2 on other grounds by Hertz Corp. v. Friend, 559 U.S. 77, 82-83 (2010). 3 III. DISCUSSION 4 “CAFA vests the federal courts with ‘original’ diversity jurisdiction over class 5 actions [of 100 or more persons] if: (1) the aggregate amount in controversy exceeds 6 $5,000,000, and (2) any class member is a citizen of a state different from any defendant.” 7 Serrano v. 180 Connect, Inc., 478 F.3d 1018, 1020-21 (9th Cir. 2007) (citing 28 U.S.C. 8 § 1332(d)). The enactment of CAFA did not alter the longstanding rule that the proponent 9 of federal jurisdiction bears the burden of establishing that jurisdiction. Abrego v. Dow 10 Chem. Co., 443 F.3d 676, 686 (9th Cir. 2006). 11 A. Amount in Controversy 12 Plaintiff’s prayer for relief is silent as to what amount of damages or restitution she 13 seeks and the FAC otherwise fails to calculate or explain how the $5,000,000 bar will be 14 met in light of the injuries alleged. ECF No. 15 at 40. Plaintiff alleges that that cost of her 15 disputed treatment, $22,500, is representative and typical of the amount charged by 16 Defendants for stem cell therapy and that “the claims of the proposed class members exceed 17 $5,000,000 in the aggregate.” Id. ¶¶ 13, 16. Plaintiff’s allegations of class numerosity state 18 that “upon information and belief,” there are “thousands of patients, dispersed throughout 19 the United States, who received Treatment from Defendants,” and “hundreds or thousands 20 of patients from California, who received Treatment from Defendants.” Id. ¶ 119. 21 Plaintiff’s allegations appear to rest solely on Defendants claim that “they ‘successfully 22 treated’ 4,000 patients between 2011 and 2016.” Id. Plaintiff does not provide any basis 23 for the claim that there are thousands or hundreds of putative class members, either in 24 California or in other states, or that the combined amount in controversy would meet the 25 jurisdictional threshold. 26 Plaintiff’s conclusory allegation that the amount in controversy exceeds $5,000,000 27 is insufficient, without supporting factual allegations, to establish that the amount in 28 controversy requirements under CAFA has been met. Ibarra v. Manheim Invs., Inc., 775 1 F.3d 1193, 1197 (9th Cir. 2015) (the proponent of federal jurisdiction “has the burden to 2 put forward evidence showing that the amount in controversy exceeds $5 million, to satisfy 3 the requirements of CAFA, and to persuade the court that the estimate of damages in 4 controversy is a reasonable one.”). A party seeking federal jurisdiction needs only to put 5 forward a “plausible allegation that the amount in controversy exceeds the jurisdictional 6 threshold,” if their allegation is not challenged by the opposing party or questioned by the 7 court. Dart Cherokee Basin Operating Co., LLC v. Owens, 574 U.S. 81, 89 (2014). 8 Furthermore, a party “is permitted to rely on ‘a chain of reasoning that includes 9 assumptions.’” Arias v. Residence Inn, 936 F.3d 920, 925 (9th Cir. 2019) (quoting Ibarra, 10 775 F.3d at 1199). However, “those assumptions cannot be pulled from thin air but need 11 some reasonable ground underlying them.” Ibarra, 775 F.3d at 1199.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hertz Corp. v. Friend
559 U.S. 77 (Supreme Court, 2010)
General Telephone Co. of Southwest v. Falcon
457 U.S. 147 (Supreme Court, 1982)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Ruhrgas Ag v. Marathon Oil Co.
526 U.S. 574 (Supreme Court, 1999)
Arbaugh v. Y & H Corp.
546 U.S. 500 (Supreme Court, 2006)
Serrano v. 180 Connect, Inc.
478 F.3d 1018 (Ninth Circuit, 2007)
In Re TFT-LCD (Flat Panel) Antitrust Litigation
781 F. Supp. 2d 955 (N.D. California, 2011)
Lira v. Herrera
427 F.3d 1164 (Ninth Circuit, 2005)
Blanca Argelia Arias v. Residence Inn by Marriott
936 F.3d 920 (Ninth Circuit, 2019)
Tosco Corp. v. Communities for a Better Environment
236 F.3d 495 (Ninth Circuit, 2001)
In re Packaged Seafood Products Antitrust Litigation
242 F. Supp. 3d 1033 (S.D. California, 2017)
Augustine v. Talking Rain Beverage Co.
386 F. Supp. 3d 1317 (S.D. California, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Mendez v. Global Institute Of Stem Cell Therapy And Research, USA, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mendez-v-global-institute-of-stem-cell-therapy-and-research-usa-casd-2022.